Cohance Lifesciences Limited (NSE:COHANCE)
India · Delayed Price · Currency is INR 542.55
-6.55 (-1.19%)
At close: Dec 5, 2025
Cohance Lifesciences Revenue
Cohance Lifesciences had revenue of 5.56B INR in the quarter ending September 30, 2025, with 115.57% growth. This brings the company's revenue in the last twelve months to 12.11B, up 25.95% year-over-year. In the fiscal year ending March 31, 2025, Cohance Lifesciences had annual revenue of 11.98B with 13.91% growth.
Revenue (ttm)
12.11B
Revenue Growth
+25.95%
P/S Ratio
17.15
Revenue / Employee
9.99M
Employees
1,212
Market Cap
207.56B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 11.98B | 1.46B | 13.91% |
| Mar 31, 2024 | 10.51B | -2.89B | -21.56% |
| Mar 31, 2023 | 13.40B | 201.07M | 1.52% |
| Mar 31, 2022 | 13.20B | 3.11B | 30.75% |
| Mar 31, 2021 | 10.10B | 1.76B | 21.10% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 549.64B |
| Aurobindo Pharma | 325.14B |
| Cipla | 279.66B |
| Zydus Lifesciences | 244.94B |
| Apollo Hospitals Enterprise | 232.65B |
| Glenmark Pharmaceuticals | 159.97B |
| Alkem Laboratories | 138.90B |
| Mankind Pharma | 135.46B |